• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

包含患者间异质性的肿瘤控制概率模型中的最佳参数:对数正态分布评估

Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.

作者信息

Keall P J, Webb S

机构信息

Department of Radiation Oncology, Stanford University, Stanford, CA, USA.

出版信息

Phys Med Biol. 2007 Jan 7;52(1):291-302. doi: 10.1088/0031-9155/52/1/019. Epub 2006 Dec 20.

DOI:10.1088/0031-9155/52/1/019
PMID:17183142
Abstract

The heterogeneity of human tumour radiation response is well known. Researchers have used the normal distribution to describe interpatient tumour radiosensitivity. However, many natural phenomena show a log-normal distribution. Log-normal distributions are common when mean values are low, variances are large and values cannot be negative. These conditions apply to radiosensitivity. The aim of this work was to evaluate the log-normal distribution to predict clinical tumour control probability (TCP) data and to compare the results with the homogeneous (delta-function with single alpha-value) and normal distributions. The clinically derived TCP data for four tumour types-melanoma, breast, squamous cell carcinoma and nodes-were used to fit the TCP models. Three forms of interpatient tumour radiosensitivity were considered: the log-normal, normal and delta-function. The free parameters in the models were the radiosensitivity mean, standard deviation and clonogenic cell density. The evaluation metric was the deviance of the maximum likelihood estimation of the fit of the TCP calculated using the predicted parameters to the clinical data. We conclude that (1) the log-normal and normal distributions of interpatient tumour radiosensitivity heterogeneity more closely describe clinical TCP data than a single radiosensitivity value and (2) the log-normal distribution has some theoretical and practical advantages over the normal distribution. Further work is needed to test these models on higher quality clinical outcome datasets.

摘要

人类肿瘤辐射反应的异质性是众所周知的。研究人员曾用正态分布来描述患者间肿瘤的放射敏感性。然而,许多自然现象呈现对数正态分布。当均值较低、方差较大且值不能为负时,对数正态分布很常见。这些条件适用于放射敏感性。这项工作的目的是评估对数正态分布以预测临床肿瘤控制概率(TCP)数据,并将结果与均匀分布(具有单个α值的δ函数)和正态分布进行比较。使用四种肿瘤类型(黑色素瘤、乳腺癌、鳞状细胞癌和淋巴结)的临床得出的TCP数据来拟合TCP模型。考虑了三种患者间肿瘤放射敏感性形式:对数正态、正态和δ函数。模型中的自由参数是放射敏感性均值、标准差和克隆源性细胞密度。评估指标是使用预测参数计算的TCP拟合的最大似然估计与临床数据的偏差。我们得出结论:(1)患者间肿瘤放射敏感性异质性的对数正态和正态分布比单一放射敏感性值更能准确描述临床TCP数据;(2)对数正态分布相对于正态分布具有一些理论和实际优势。需要进一步开展工作,在更高质量的临床结果数据集上测试这些模型。

相似文献

1
Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.包含患者间异质性的肿瘤控制概率模型中的最佳参数:对数正态分布评估
Phys Med Biol. 2007 Jan 7;52(1):291-302. doi: 10.1088/0031-9155/52/1/019. Epub 2006 Dec 20.
2
Evaluation of dose-response models and parameters predicting radiation induced pneumonitis using clinical data from breast cancer radiotherapy.利用乳腺癌放疗的临床数据评估预测放射性肺炎的剂量反应模型和参数。
Phys Med Biol. 2005 Aug 7;50(15):3535-54. doi: 10.1088/0031-9155/50/15/004. Epub 2005 Jul 19.
3
Limitations of a TCP model incorporating population heterogeneity.纳入人群异质性的TCP模型的局限性。
Phys Med Biol. 2005 Aug 7;50(15):3571-88. doi: 10.1088/0031-9155/50/15/006. Epub 2005 Jul 19.
4
A general tumour control probability model for non-uniform dose distributions.一种针对非均匀剂量分布的通用肿瘤控制概率模型。
Math Med Biol. 2008 Jun;25(2):171-84. doi: 10.1093/imammb/dqn012. Epub 2008 May 29.
5
Comparison of predicted and clinical response to radiotherapy: a radiobiology modelling study.放疗预测反应与临床反应的比较:一项放射生物学建模研究。
Acta Oncol. 2009;48(4):584-90. doi: 10.1080/02841860802637757.
6
The impact of different dose-response parameters on biologically optimized IMRT in breast cancer.
Phys Med Biol. 2008 May 21;53(10):2733-52. doi: 10.1088/0031-9155/53/10/019. Epub 2008 May 1.
7
EUCLID: an outcome analysis tool for high-dimensional clinical studies.EUCLID:一种用于高维临床研究的结果分析工具。
Phys Med Biol. 2007 Mar 21;52(6):1705-19. doi: 10.1088/0031-9155/52/6/011. Epub 2007 Feb 27.
8
The use of spatial dose gradients and probability density function to evaluate the effect of internal organ motion for prostate IMRT treatment planning.利用空间剂量梯度和概率密度函数评估前列腺调强放疗治疗计划中内部器官运动的影响。
Phys Med Biol. 2007 Mar 7;52(5):1469-84. doi: 10.1088/0031-9155/52/5/016. Epub 2007 Feb 12.
9
Analytic investigation into effect of population heterogeneity on parameter ratio estimates.群体异质性对参数比率估计影响的分析研究。
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1323-30. doi: 10.1016/j.ijrobp.2007.07.2355. Epub 2007 Sep 20.
10
Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression.预测异质性肿瘤集合体的放射控制概率:使用闭式表达式进行数据分析和参数估计
Phys Med Biol. 1998 Aug;43(8):2159-78. doi: 10.1088/0031-9155/43/8/012.

引用本文的文献

1
Practical parameter identifiability and handling of censored data with Bayesian inference in mathematical tumour models.在数学肿瘤模型中,通过贝叶斯推断进行实用参数可识别性和有界数据处理。
NPJ Syst Biol Appl. 2024 Aug 14;10(1):89. doi: 10.1038/s41540-024-00409-6.
2
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.黑色素瘤进展及治疗耐药的机制:癌症干细胞样细胞的作用
Cancers (Basel). 2024 Jan 22;16(2):470. doi: 10.3390/cancers16020470.
3
Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI.
利用从 mpMRI 获得的患者特定肿瘤位置和克隆源密度,对前列腺调强放疗进行体素级生物优化。
Radiat Oncol. 2020 Jul 13;15(1):172. doi: 10.1186/s13014-020-01568-6.
4
Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy.非小细胞肺癌放射治疗技术与实施的进展:调强放射治疗、质子治疗和立体定向体部放射治疗的优势
Transl Lung Cancer Res. 2017 Apr;6(2):131-147. doi: 10.21037/tlcr.2017.04.04.
5
Evaluation of the deformation and corresponding dosimetric implications in prostate cancer treatment.评估前列腺癌治疗中的变形及其相应的剂量学影响。
Phys Med Biol. 2012 Sep 7;57(17):5361-79. doi: 10.1088/0031-9155/57/17/5361. Epub 2012 Aug 3.
6
In silico modelling of treatment-induced tumour cell kill: developments and advances.治疗诱导肿瘤细胞杀伤的计算机模型:进展与突破。
Comput Math Methods Med. 2012;2012:960256. doi: 10.1155/2012/960256. Epub 2012 Jul 12.